Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments
Atopic Dermatitis, Ichthyosis, Psoriasis
About this trial
This is an interventional other trial for Atopic Dermatitis
Eligibility Criteria
Inclusion Criteria:
- Affected children must have moderate to severe AD or another skin condition that causes itch, experience itch, understand English, and be able to complete an English-based survey
- Any child with a potentially disfiguring skin condition or change in appearance related to disease/intervention will be considered eligible. Parents of children with such conditions will also be asked to participate. Children and parents must also understand English and be able to complete an English-based survey
Sub-study Inclusion Criteria:
- Patients ages 8 years-17 years with a diagnosis of mild AD
- Patients ages 6 months to 8 years with a diagnosis of AD (any severity)
- English speaking
- Families must be able to access the internet (e.g., Skype or Facetime) for follow-up, or be able to come for follow-up within five days of an AD flare and again when improved.
- Patients with developmental delay and/or a behavioral disorder that would preclude participation in form completion will not be eligible for this study.
Sites / Locations
- Department of Dermatology, Northwestern University Feinberg School of Medicine and Lurie Children's Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Other
Other
Other
Other
Itch Questionnaire and Interview
Stigma Questionnaire and Interview
Validation Questionnaire and Interview-Moderate to Severe
Validation Questionnaire and Interview-Mild
Up to 30 dyads of patients ages 8-17 and their parents/caregivers, as well as up to 20 parents of children ages 6mo-7 years, will participate in semi-structured interviews to evaluate the new and modified items (questions) written for the PIQ-C questionnaire
To assess stigma, up to 20 children ages 8-17 and 20 parents of children ages 5-12, will participate in semi-structured interviews to evaluate the modified Neuro-QoL stigma questionnaire. This questionnaire includes new skin-specific stigma items and existing items modified for use with children having a skin or other condition that may negatively affect their appearance
For validation, up to 200 parent/child dyads ages 5-17 with a diagnosis of moderate to severe AD during the previous 6 months will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status.
For validation, up to 90 parent/child dyads ages 0-17 with a diagnosis of mild AD will participate in teledermatology or in-person semi-structured interviews as follow-up to validate PRO measures in a large cohort of itch-specific pediatric skin conditions, specifically AD. Furthermore, this portion of the study will validate generic PROMIS measures of AD subjects' environmental stressors, illness flares, socio-demographic differences based on race/ethnicity and family income status for mild patients.